Loading...
Curaleaf Holdings, Inc.
CURA.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$5.22
CA$0.44(9.21%)

Over the last four quarters, Curaleaf Holdings, Inc. achieved steady financial progress, growing revenue from $337.42M in Q1 2024 to $331.05M in Q4 2024. Gross profit stayed firm with margins at 48% in Q4 2024 versus 37% in Q1 2024. Operating income totaled -$9.28M in Q4 2024, maintaining a -3% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $26.07M. Net income dropped to -$77.56M, with EPS at $0.00. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan